<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JBX</journal-id>
<journal-id journal-id-type="hwp">spjbx</journal-id>
<journal-id journal-id-type="nlm-ta">J Biomol Screen</journal-id>
<journal-title>Journal of Biomolecular Screening</journal-title>
<issn pub-type="ppub">1087-0571</issn>
<issn pub-type="epub">1552-454X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1087057112441012</article-id>
<article-id pub-id-type="publisher-id">10.1177_1087057112441012</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Screening and Characterization of Human Monoglyceride Lipase Active Site Inhibitors Using Orthogonal Binding and Functional Assays</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Clemente</surname><given-names>José C.</given-names></name>
<xref ref-type="aff" rid="aff1-1087057112441012">1</xref>
<xref ref-type="aff" rid="aff2-1087057112441012">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nulton</surname><given-names>Erica</given-names></name>
<xref ref-type="aff" rid="aff2-1087057112441012">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nelen</surname><given-names>Marina</given-names></name>
<xref ref-type="aff" rid="aff2-1087057112441012">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Todd</surname><given-names>Matthew J.</given-names></name>
<xref ref-type="aff" rid="aff2-1087057112441012">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maguire</surname><given-names>Diane</given-names></name>
<xref ref-type="aff" rid="aff3-1087057112441012">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schalk-Hihi</surname><given-names>Céline</given-names></name>
<xref ref-type="aff" rid="aff3-1087057112441012">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kuo</surname><given-names>Lawrence C.</given-names></name>
<xref ref-type="aff" rid="aff3-1087057112441012">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Sui-Po</given-names></name>
<xref ref-type="aff" rid="aff4-1087057112441012">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Flores</surname><given-names>Christopher M.</given-names></name>
<xref ref-type="aff" rid="aff4-1087057112441012">4</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Kranz</surname><given-names>James K.</given-names></name>
<xref ref-type="aff" rid="aff2-1087057112441012">2</xref>
<xref ref-type="aff" rid="aff5-1087057112441012">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-1087057112441012"><label>1</label>Author’s current address, GlaxoSmithKline, Oncology Research &amp; Development, Collegeville, PA, USA</aff>
<aff id="aff2-1087057112441012"><label>2</label>Lead Generation Biology, Janssen Research &amp; Development, LLC, Spring House, PA, USA</aff>
<aff id="aff3-1087057112441012"><label>3</label>Structural Biology, Janssen Research &amp; Development, LLC, Spring House, PA, USA</aff>
<aff id="aff4-1087057112441012"><label>4</label>Analgesics Research, Janssen Research &amp; Development, LLC, Spring House, PA, USA</aff>
<aff id="aff5-1087057112441012"><label>5</label>Author’s current address, Biopharmaceuticals Research &amp; Development, GlaxoSmithKline, King of Prussia, PA, USA</aff>
<author-notes>
<corresp id="corresp1-1087057112441012">James K. Kranz, PhD, Biopharmaceuticals Research &amp; Development, GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406, USA Email: <email>james.k.kranz@gsk.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>17</volume>
<issue>5</issue>
<fpage>629</fpage>
<lpage>640</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>31</day>
<month>10</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>11</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 Society for Laboratory Automation and Screening</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Laboratory Automation and Screening</copyright-holder>
</permissions>
<abstract>
<p>Endocannabinoids such as 2-arachidonylglycerol (2-AG) are ligands for cannabinoid receptors that contribute to the transmission and modulation of pain signals. The antinociceptive effect of exogenous 2-AG suggests that inhibition of monoglyceride lipase (MGLL), the enzyme responsible for degrading 2-AG and arresting signaling, may be a target for pain modulation. Here we describe the characterization of MGLL ligands following a high-throughput screening campaign. Ligands were discovered using ThermoFluor, a label-free affinity-based screening tool that measures ligand binding via modulation of protein thermal stability. A kinetic fluorescent assay using the substrate 4-methylcoumarin butyrate was used to counterscreen confirmed HTS positives. A comparison of results from binding and inhibition assays allowed elucidation of compound mechanism of action. We demonstrate the limit of each technology and the benefits of using orthogonal assay techniques in profiling compounds.</p>
</abstract>
<kwd-group>
<kwd>monoglyceride lipase</kwd>
<kwd>2-arachidonylglycerol</kwd>
<kwd>endocannabinoids</kwd>
<kwd>high-throughput screening</kwd>
<kwd>ThermoFluor</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1087057112441012" sec-type="intro">
<title>Introduction</title>
<p>Cannabis has been used as a natural analgesic for centuries, although not without well-documented side effects. Perception of a noxious stimulus (nociception) is a complex sensory phenomenon, dependent on the type and intensity of the stimulus as well as the particular pain pathways activated. Both natural and exogenous cannabinoids can produce antinociception mediated through the cannabinoid receptors CB1 and CB2,<sup><xref ref-type="bibr" rid="bibr1-1087057112441012">1</xref>,<xref ref-type="bibr" rid="bibr2-1087057112441012">2</xref></sup> which have been identified both peripherally and in the central nervous systems. Animal studies demonstrate that cannabinoids can be as effective as morphine in suppressing the physical reactions to acute pain.<sup><xref ref-type="bibr" rid="bibr3-1087057112441012">3</xref><xref ref-type="bibr" rid="bibr4-1087057112441012"/>–<xref ref-type="bibr" rid="bibr5-1087057112441012">5</xref></sup> Unfortunately, the use of exogenous cannabinoids can produce severe motor deficits (including sedation, hypothermia, and catalepsy), complicating the ability to interpret the phenotype of cannabinoid agonists. Effective modulation of pain via the cannabinoid receptors depends on finding pharmacological agents that act peripherally on pain-sensing mechanisms.</p>
<p>A defining characteristic of neurotransmitter systems is rapid onset of signaling, followed by rapid signal inactivation. The endocannabinoid 2-AG is produced on demand by neurons and functions near its site of synthesis; signaling is typically terminated by uptake and enzymatic degradation of the neurotransmitter via monoglyceride lipase (or monoacylglycerol lipase, MGLL; EC 3.1.1.23).<sup><xref ref-type="bibr" rid="bibr6-1087057112441012">6</xref>,<xref ref-type="bibr" rid="bibr7-1087057112441012">7</xref></sup> Inhibition of MGLL would increase 2-AG levels, which might in turn prolong its nociceptive effect, enhancing retrograde signaling.<sup><xref ref-type="bibr" rid="bibr4-1087057112441012">4</xref>,<xref ref-type="bibr" rid="bibr8-1087057112441012">8</xref></sup> Targeting the cannabinoid receptor system for antinociceptive therapy through inhibition of endocannabinoid hydrolysis may provide for greater selectivity and fewer adverse effects, as the resulting increase in endocannabinoid concentration occurs at the site of action, not systemically.</p>
<p>MGLL belongs to the α/β hydrolase family containing a classical Ser-His-Asp catalytic triad,<sup><xref ref-type="bibr" rid="bibr9-1087057112441012">9</xref>,<xref ref-type="bibr" rid="bibr10-1087057112441012">10</xref></sup> similar to that of other lipases.<sup><xref ref-type="bibr" rid="bibr11-1087057112441012">11</xref></sup> In designing an activity counterscreen for use in profiling hits from a high-throughput screen (HTS), several historical procedures were considered. Ideally, one would use the physiologically relevant substrate 2-AG, but complications arise due to the natural isomerization reaction of 2-AG to 1-AG, yielding a mixture of substrates with mixed kinetic properties. Use of 2-AG could necessitate the use of chromatographic techniques to separate substrate and products.<sup><xref ref-type="bibr" rid="bibr12-1087057112441012">12</xref>,<xref ref-type="bibr" rid="bibr13-1087057112441012">13</xref></sup> Radiolabeled substrates are commonly used for monitoring enzyme activity where one can distinguish between the various reaction products but are labor intensive, are low throughput, and may require handling restrictions. Alternatively, fluorescent-based substrate analogues can be exploited to yield a real-time, rate-based assay.<sup><xref ref-type="bibr" rid="bibr14-1087057112441012">14</xref></sup></p>
<p>Here, we demonstrate that MGLL effectively used several coumarin-based substrates with varying lengths of aliphatic chains, and we employed these in developing a rate-based assay. The coumarin-based assay was exploited to profile screening hits generated using ThermoFluor<xref ref-type="fn" rid="fn1-1087057112441012">*</xref> technology, a miniaturized, high-throughput thermal stability assay that detects compound binding through perturbations in the free energy of protein stability. ThermoFluor was chosen as the primary assay for HTS to detect all small molecules interacting with MGLL, anticipating a further classification of confirmed screening hits based on their effect on enzyme activity. We present a comparison of compound binding and inhibition, which shows distinct groupings of compounds differentiated by assay limitations and mode of action.</p>
</sec>
<sec id="section2-1087057112441012" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1087057112441012">
<title>Reagents</title>
<p>Unless otherwise stated below, materials were obtained from commercial sources. 4-Methylcoumarin (or 4-methylumbelliferyl)–labeled substrates, as well as coumarin- (umbelliferyl-) arachidonate, were from Sigma-Aldrich (St. Louis, MO).</p>
</sec>
<sec id="section4-1087057112441012">
<title>Enzyme expression and purification</title>
<p>A detailed description of MGLL cloning, expression, and purification was published elsewhere.<sup><xref ref-type="bibr" rid="bibr15-1087057112441012">15</xref></sup> In brief, the cDNA for MGLL (amino acids 11–313) was cloned from human brain DNA, ligated into the modified pENTR 11cLIC vector (Invitrogen, Carlsbad, CA), and transfected into insect cells using the BaculoDirect Baculovirus Expression System (Invitrogen). The viral stock was propagated for two more amplifications at a low multiplicity of infection (MOI) to render a P2 virus stock and expanded to generate a high-titer P3 stock by infecting Sf9 cells in suspension at a MOI of 0.3, harvesting the virus after 72 h.</p>
<p>Large-scale expression was done in 2-L shake flasks or WAVE bioreactors (GE Healthcare, Piscataway, NJ), infecting Sf9 cells at a density of 1.5 × 10<sup>6</sup> cells/mL with an MOI of 1. Infected cultures were maintained at 27 °C under constant shaking at 140 rpm. Cells were harvested 65 to 72 h postinfection by centrifugation. Cell viability was determined by Guava ViaCount (Millipore, Billerica, MA) or trypan blue, which was routinely 60% to 80% at time of harvest. Cell pellets were thawed and resuspended in buffer A (50 mM HEPES [pH 7.5], 400 mM NaCl, 5% glycerol, 0.05% β-mercaptoethanol, [1×] Complete EDTA-free protease inhibitor cocktail tablets [Roche, Basel, Switzerland]), homogenized and mechanically lysed with a micro-fluidizer processor (Microfluidics, Newton, MA), and clarified by centrifugation (40 000 <italic>g</italic>, 1 h). The lysate was loaded on a 1-mL His-Trap FF crude column and ÄKTAxpress system (GE-Healthcare) at 4 °C. MGLL was eluted with five column volumes of buffer A containing 400 mM imidazole. The elution peak was loaded onto a Superdex 200 HR 16/60 (GE Healthcare, Piscataway, NJ) preequilibrated with buffer B (50 mM HEPES [pH 7.5] buffer containing 200 mM NaCl, 2% glycerol, 1 mM dithiothreitol).</p>
</sec>
<sec id="section5-1087057112441012">
<title>Substrate solubility</title>
<p>Stock substrate solutions were dissolved in 100% DMSO at concentrations of 5 or 60 mM. Twelve serial twofold dilutions were created in 100% DMSO in a 384-well polypropylene plate (Greiner Bio-One, Monroe, NC). Substrate dilutions were dispensed (0.35 µL) into a 384 UVStar plate (Greiner Bio-one) using a Cartesian Hummingbird capillary liquid-handling instrument (Genomics Solutions, Ann Arbor, MI). Then, 50 µL buffer C (20 mM PIPES [pH 7.0], 150 mM NaCl) was added and mixed manually using a multichannel pipettor. Absorbance scans of the substrate aqueous dilutions were measured from 230 to 700 nm at 25 °C (Safire<sup><xref ref-type="bibr" rid="bibr2-1087057112441012">2</xref></sup>; Tecan, Männedorf, Switzerland). Absorbance at 310 nm and scattering at 600 nm were used to determine the Molar Extinction Coefficient (ϵ<sub>310</sub>) and solubility of the substrate, respectively.</p>
</sec>
<sec id="section6-1087057112441012">
<title>Rate-based assays</title>
<p>All rate-based assays were performed in black 384-well polypropylene PCR microplates (ABgene, Surrey, UK) in a total volume of 30 µL. The fluorescence change due to substrate cleavage at 37 °C was monitored with excitation and emission wavelengths of 335 and 440 nm (10 nm bandwidth), respectively, measured on a Safire<sup><xref ref-type="bibr" rid="bibr2-1087057112441012">2</xref></sup> plate reader (Tecan). Assays plates were loaded with substrate dissolved in buffer C (25 µL at 1.2 × final substrate concentration, in 1 × buffer C + 0.003% Triton ”Triton” should be replaced with “Triton X-100”.), followed by enzyme (5 µL of a 6× solution in 1× buffer, final [MGLL] = 10 nM) to initiate the reaction. The initial rate was measured for 3 min while reactions behaved in a zero order manner. Fluorescence was converted to concentration using a coumarin standard curve. Substrate showed an inner-filter effect on product fluorescence above 600 µM (~ 3.0 absorbance units ~ 310 nm). Activity at these concentrations was not used to determine kinetic constants.</p>
<p>Compounds were dissolved in 100% DMSO to 10 mM, and 11-point dilutions series (1:2 dilutions, also in 100% DMSO) were generated. Compounds (45 nL) were predispensed from compound dilution plates into assay plates using the Hummingbird. These predispensed plates were stable for months (data not shown) but were typically used within hours. Plates were assayed as above, after diluting compound with 25 µL of 1.2× substrate and initiating reactions with 5 µL 6× MGLL in buffer C. The final concentration of MGLL in enzymatic assays ranged from 0.5 to 40 nM but was typically 2 nM in compound inhibition assays. Final compound concentrations ranged from 0.015 to 15 µM, except when assayed at a single concentration (noted below).</p>
<p>The kinetic constants for MGLL enzymatic activity and inhibition were obtained from a fit of data to <xref ref-type="disp-formula" rid="disp-formula1-1087057112441012">equation (1)</xref>.</p>
<p><disp-formula id="disp-formula1-1087057112441012">
<mml:math display="block" id="math1-1087057112441012">
<mml:mrow>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mrow>
<mml:mi>o</mml:mi>
<mml:mi>b</mml:mi>
<mml:mi>s</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>k</mml:mi>
<mml:mrow>
<mml:mi>c</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>t</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mtext>E</mml:mtext>
<mml:mtext>t</mml:mtext>
</mml:msub>
</mml:mrow>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mtext>S</mml:mtext>
<mml:mo>]</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mtext>S</mml:mtext>
<mml:mo>]</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mi>m</mml:mi>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo>[</mml:mo>
<mml:mtext>I</mml:mtext>
<mml:mo>]</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mfrac>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1087057112441012" xlink:href="10.1177_1087057112441012-eq1.tif"/></disp-formula></p>
<p>v<sub>obs</sub> is the observed rate of enzyme activity at each substrate concentration, [S]; k<sub>cat</sub> is the catalytic constant; [E<sub>t</sub>] is the total active enzyme concentration (where V<sub>max</sub> = [E<sub>t</sub>]k<sub>cat</sub>); K<sub>m</sub> is the apparent substrate dissociation constant; [I] is the inhibitor concentration; and K<sub>i</sub> is the inhibitor dissociation constant. Intrinsic kinetic constants, k<sub>cat</sub> and K<sub>m</sub>, were determined in the absence of inhibit or from the initial linear rates of 11 substrate concentrations ranging from 0 to 600 µM. Inhibitor dissociation constants, K<sub>i</sub>, were determined by varying both substrate and inhibitor concentrations.</p>
<p>The IC<sub>50</sub> values for the experimental compounds were determined from the fit of <xref ref-type="disp-formula" rid="disp-formula2-1087057112441012">equation (2)</xref> to the dose-response plot of the fractional activity as a function of inhibitor concentration.</p>
<p><disp-formula id="disp-formula2-1087057112441012">
<mml:math display="block" id="math2-1087057112441012">
<mml:mrow>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mrow>
<mml:mi>min</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mi>o</mml:mi>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>v</mml:mi>
<mml:mrow>
<mml:mi>m</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>n</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">[</mml:mo>
<mml:mtext>I</mml:mtext>
<mml:mo stretchy="false">]</mml:mo>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mi>h</mml:mi>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula2-1087057112441012" xlink:href="10.1177_1087057112441012-eq2.tif"/></disp-formula></p>
<p>where v<sub>i</sub> is the fractional activity of the enzyme at inhibitor concentration [I], v<sub>o</sub> is the enzyme activity at zero inhibitor concentration, v<sub>min</sub> is the minimum enzyme activity at saturating inhibitor concentrations, IC<sub>50</sub> is the inhibitor concentration that gives 50% activity, and h is the Hill coefficient.</p>
<p>For inhibitors that have been determined to be kinetically competitive with the substrate, the IC<sub>50</sub> is related to K<sub>i</sub>, K<sub>m</sub>, and [S] by <xref ref-type="disp-formula" rid="disp-formula3-1087057112441012">equation (3)</xref>.</p>
<p><disp-formula id="disp-formula3-1087057112441012">
<mml:math display="block" id="math3-1087057112441012">
<mml:mrow>
<mml:mi>I</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">[</mml:mo>
<mml:mtext>S</mml:mtext>
<mml:mo stretchy="false">]</mml:mo>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mi>m</mml:mi>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula3-1087057112441012" xlink:href="10.1177_1087057112441012-eq3.tif"/></disp-formula></p>
<p>The IC<sub>50</sub> approaches K<sub>i</sub> at [S] &lt;&lt; K<sub>m</sub>. At [S] = K<sub>m</sub>, IC<sub>50</sub> = 2 · K<sub>i</sub>. The substrate concentration (10 µM) used for compound analysis was 14-fold below the K<sub>m</sub> (134 ± 5 µM, determined below). Percent inhibition values were determined by comparing the enzyme rate using 4 µM compound (v<sub>i</sub>) with the enzyme rate in the absence of compound (v<sub>0</sub>).</p>
</sec>
<sec id="section7-1087057112441012">
<title>ThermoFluor assay</title>
<p>Plate-based protein thermal stability of MGLL was assayed by ThermoFluor using instruments available from Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. (Exton, PA). Details of the ThermoFluor-based protein stability assay are described elsewhere.<sup><xref ref-type="bibr" rid="bibr16-1087057112441012">16</xref><xref ref-type="bibr" rid="bibr17-1087057112441012"/><xref ref-type="bibr" rid="bibr18-1087057112441012"/>–<xref ref-type="bibr" rid="bibr19-1087057112441012">19</xref></sup> Briefly, protein unfolding is induced by increasing temperature and detected by monitoring the fluorescent probe, 1,8-ANS, which exhibits a change in fluorescence associated with protein unfolding due to noncovalent, nonspecific dye association with hydrophobic protein residues buried in the native state.</p>
<p>For ligand-binding studies, compounds (45 nL) were dispensed from the same compound dilution plates described above into black 384-well polypropylene PCR (ABgene) assay plates using a Cartesian Hummingbird. Protein at a concentration of 0.05 mg/mL in 50 mM PIPES (pH 7), 200 mM NaCl, 100 µM 1,8-ANS, and 0.001% Tween-20 was added to assay plates (3 µL) containing predispensed compound. Wells were overlaid with silicone oil (1 µL, type DC 200; Fluka, St. Louis, MO) to prevent evaporation during thermal cycling. Final compound concentrations varied from 150 to 0.15 µM, except when assayed at a single concentration (noted below). Assay plates were heated at a rate of 1 °C/min for all experiments over a temperature range sufficient to measure protein unfolding. Fluorescence was measured by continuous illumination with UV light (Hamamatsu LC6; Hamamatsu, Bridgewater, NJ) supplied via fiber optics and filtered through a custom band-pass filter (380–400 nm; &gt;6 OD cutoff; Omega Optical, Battleboro, VT). Fluorescence emission was detected by measuring light intensity using a CCD camera (Sensys, Roper Scientific, Trenton, NJ) filtered to detect emission at 500 ± 25 nm (Omega Optical, Battleboro, VT), resulting in simultaneous and independent readings of all 384 wells. One or more images were collected at each temperature, and the sum (or average of the sums) of the pixel intensity associated with a given well versus temperature was fit to standard equations, yielding the <italic>T<sub>m</sub></italic>, as described in the Data Analysis section.</p>
<p>Thermal stability profiles obtained using ThermoFluor were fit to <xref ref-type="disp-formula" rid="disp-formula1-1087057112441012">equation (1)</xref> to determine the <italic>T<sub>m</sub></italic>.<sup><xref ref-type="bibr" rid="bibr16-1087057112441012">16</xref>,<xref ref-type="bibr" rid="bibr17-1087057112441012">17</xref></sup></p>
<p><disp-formula id="disp-formula4-1087057112441012">
<mml:math display="block" id="math4-1087057112441012">
<mml:mrow>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mtext>F</mml:mtext>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>m</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>m</mml:mi>
<mml:mtext>F</mml:mtext>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>m</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mtext>U</mml:mtext>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>m</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mtext>F</mml:mtext>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>m</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>m</mml:mi>
<mml:mtext>U</mml:mtext>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>m</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mi>G</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:mi>R</mml:mi>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula4-1087057112441012" xlink:href="10.1177_1087057112441012-eq4.tif"/>
</disp-formula></p>
<p>where</p>
<p><disp-formula id="disp-formula5-1087057112441012">
<mml:math display="block" id="math5-1087057112441012">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mi>G</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>G</mml:mi>
<mml:mtext>U</mml:mtext>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>G</mml:mi>
<mml:mtext>b</mml:mtext>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula5-1087057112441012" xlink:href="10.1177_1087057112441012-eq5.tif"/>
</disp-formula></p>
<p><disp-formula id="disp-formula6-1087057112441012">
<mml:math display="block" id="math6-1087057112441012">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>G</mml:mi>
<mml:mtext>U</mml:mtext>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>H</mml:mi>
<mml:mtext>U</mml:mtext>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mo>,</mml:mo>
<mml:mtext>U</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mtext>r</mml:mtext>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>S</mml:mi>
<mml:mtext>U</mml:mtext>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mo>,</mml:mo>
<mml:mtext>U</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mi>ln</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mtext>r</mml:mtext>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula6-1087057112441012" xlink:href="10.1177_1087057112441012-eq6.tif"/></disp-formula></p>
<p><disp-formula id="disp-formula7-1087057112441012">
<mml:math display="block" id="math7-1087057112441012">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>G</mml:mi>
<mml:mi>b</mml:mi>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>H</mml:mi>
<mml:mi>b</mml:mi>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mtext>0</mml:mtext>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>b</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mtext>0</mml:mtext>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>S</mml:mi>
<mml:mi>b</mml:mi>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mtext>0</mml:mtext>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mrow>
<mml:mi>p</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>b</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mi>ln</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mtext>0</mml:mtext>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>.</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula7-1087057112441012" xlink:href="10.1177_1087057112441012-eq7.tif"/></disp-formula></p>
<p>Binding affinities are determined from a ligand concentration-dependent increase in the <italic>T<sub>m</sub></italic> of MGLL. The expression of total ligand concentration, L<sub>t</sub>, and total protein concentration, P<sub>t</sub>, needed to raise the <italic>T<sub>m</sub></italic> to a given value is</p>
<p><disp-formula id="disp-formula8-1087057112441012">
<mml:math display="block" id="math8-1087057112441012">
<mml:mrow>
<mml:msub>
<mml:mi>L</mml:mi>
<mml:mi>t</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mtext>N</mml:mtext>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mi>t</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:mfrac>
<mml:mo>+</mml:mo>
<mml:mfrac>
<mml:mn>1</mml:mn>
<mml:mrow>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mtext>N</mml:mtext>
</mml:msub>
<mml:msub>
<mml:mi>K</mml:mi>
<mml:mtext>a</mml:mtext>
</mml:msub>
</mml:mrow>
</mml:mfrac>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula8-1087057112441012" xlink:href="10.1177_1087057112441012-eq8.tif"/>
</disp-formula></p>
<p><disp-formula id="disp-formula9-1087057112441012">
<mml:math display="block" id="math9-1087057112441012">
<mml:mtable>
<mml:mtr>
<mml:mtd>
<mml:msub>
<mml:mi>L</mml:mi>
<mml:mi>t</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>H</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>S</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mi>ln</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:mi>R</mml:mi>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:msup>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>×</mml:mo>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mi>t</mml:mi>
</mml:msub>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:mfrac>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>+</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>H</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>S</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>U</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mi>ln</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mi>r</mml:mi>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:mi>R</mml:mi>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>×</mml:mo>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:mrow>
<mml:msup>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>b</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>H</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>b</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>−</mml:mo>
<mml:mi>T</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>b</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>S</mml:mi>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>Δ</mml:mi>
<mml:mi>b</mml:mi>
</mml:msub>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>p</mml:mi>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mi>ln</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mrow>
<mml:mi>T</mml:mi>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>T</mml:mi>
<mml:mtext>0</mml:mtext>
</mml:msub>
</mml:mrow>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>/</mml:mo>
<mml:mrow>
<mml:mi>R</mml:mi>
<mml:mi>T</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:msup>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:math>
<graphic alternate-form-of="disp-formula9-1087057112441012" xlink:href="10.1177_1087057112441012-eq9.tif"/>
</disp-formula></p>
<p>where K<sub>N</sub> is the equilibrium constant for folding (equivalent to the inverse of the unfolding equilibrium constant, K<sub>U</sub>), and K<sub>a</sub> is the equilibrium constant for ligand association (equivalent to the inverse of the dissociation constant, K<sub>D</sub>). <xref ref-type="disp-formula" rid="disp-formula9-1087057112441012">Equation (6b)</xref> is transcendental with respect to temperature and thus cannot be solved explicitly for <italic>T<sub>m</sub></italic> as a function of total ligand concentration, L<sub>t</sub>.<sup><xref ref-type="bibr" rid="bibr16-1087057112441012">16</xref>,<xref ref-type="bibr" rid="bibr17-1087057112441012">17</xref></sup> Therefore, estimates of ligand binding require an inversion of the dependent and independent variables.</p>
</sec>
</sec>
<sec id="section8-1087057112441012" sec-type="results">
<title>Results</title>
<sec id="section9-1087057112441012">
<title>Solubility of aliphatic substrates</title>
<p>The natural substrate for MGLL is 2-AG (<xref ref-type="fig" rid="fig1-1087057112441012"><bold>Fig. 1A</bold></xref>). Five different 4-methylcoumarin (4-MC-) and coumarin (C-) based acyl-substrates with various aliphatic chain lengths were selected based on their commercial availability and were explored as a mimetic of 2-AG in MGLL activity assays (<xref ref-type="fig" rid="fig1-1087057112441012"><bold>Fig. 1B</bold></xref>). The substrates selected for MGLL assays also have been used previously for the analysis of lipase activity in other systems.<sup><xref ref-type="bibr" rid="bibr20-1087057112441012">20</xref><xref ref-type="bibr" rid="bibr21-1087057112441012"/>–<xref ref-type="bibr" rid="bibr22-1087057112441012">22</xref></sup> Prior to testing for enzymatic hydrolysis, substrate solubility was measured spectrophotometrically. Substrate absorbance was measured as a function of concentration, monitoring both the absorbance in DMSO at the peak wavelength (<xref ref-type="fig" rid="fig2-1087057112441012"><bold>Fig. 2A</bold></xref>) and the absorbance at longer, nonabsorbing wavelengths (600 nm, to assay solubility from light scattering). The absorbance of 4-methylcoumarin butyrate (4MC-B) substrate exhibited peak absorbance at 285 nm and 310 nm, with ϵ<sub>310 nm</sub> = 6000 M<sup>−1</sup>cm<sup>−1</sup> in DMSO (<xref ref-type="fig" rid="fig2-1087057112441012"><bold>Fig. 2A</bold></xref>, inset), and insignificant scattering at 600 nm (<xref ref-type="fig" rid="fig2-1087057112441012"><bold>Fig. 2C</bold></xref>), consistent with solubility &gt;400 µM in buffer C.</p>
<fig id="fig1-1087057112441012" position="float">
<label>Figure 1.</label>
<caption>
<p>Monoglyceride lipase (MGLL) substrates. (<bold>A</bold>) Hydrolysis reaction for the native substrate 2-arachidonylglycerol (2AG) and the fluorescent surrogate, 4-methylcoumarin butyrate (4MC-B). (<bold>B</bold>) Coumarin-based substrates employed in MGLL activity assays.</p>
</caption>
<graphic xlink:href="10.1177_1087057112441012-fig1.tif"/>
</fig>
<fig id="fig2-1087057112441012" position="float">
<label>Figure 2.</label>
<caption>
<p>UV/Vis analysis of substrates. Absorbance scans of (<bold>A</bold>) 4-methylcoumarin butyrate (4MC-B) or (<bold>B</bold>) coumarin-arachidonate (C-A). Insets plot peak absorbance at 310 nm versus concentration of substrate. The data demonstrate solubility limits via increased scattering at 600 nm (<bold>C</bold>) and nonlinear peak absorbance (panels <bold>A</bold>, <bold>B</bold>, inset) versus concentration for 4MC-B (closed symbols) and C-A (open symbols).</p>
</caption>
<graphic xlink:href="10.1177_1087057112441012-fig2.tif"/>
</fig>
<p>The coumarin-arachidonate (C-A) substrate was characterized by a similar absorbance at 285 nm and 310 nm, and ϵ<sub>310 nm</sub> = 5800 M<sup>−1</sup>cm<sup>−1</sup> (<xref ref-type="fig" rid="fig2-1087057112441012"><bold>Fig. 2B</bold></xref>), but displayed significant scatter at 600 nm above 100 µM (<xref ref-type="fig" rid="fig2-1087057112441012"><bold>Fig. 2C</bold></xref>), the apparent solubility limit of this substrate. The 4-methylcoumarin esterate (4MC-E), 4-methylcoumarin oleate (4MC-O), and 4-methylcoumarin palmitate (4MC-P) substrates had significantly lower apparent extinction coefficients, consistent with impure material or incomplete dissolution. Consistent with the latter interpretation, these substrates showed significant light scattering at 600 nm (even at 10 mM in 100% DMSO), with solubility limits decreasing as a function of increasing aliphatic chain length (<xref ref-type="fig" rid="fig1-1087057112441012"><bold>Fig. 1B</bold></xref>). For reasons of solubility and selectivity, unless otherwise stated, all subsequent kinetic assays used 4MC-B due to its higher solubility.</p>
</sec>
<sec id="section10-1087057112441012">
<title>4MC-B kinetic constants and solvent effect on MGLL activity</title>
<p>Steady-state rates for the hydrolysis of 4MC-B were measured under initial-rate conditions (<xref ref-type="fig" rid="fig3-1087057112441012"><bold>Fig. 3A</bold></xref>). The rate of product formation was determined within 3 min of reaction initiation, where less than 5% of the substrate was hydrolyzed. A plot showing the rate of product formation as a function of substrate concentration is hyperbolic and was fit to the Henri-Michaelis-Menten equation (<xref ref-type="fig" rid="fig3-1087057112441012"><bold>Fig. 3B</bold></xref>), yielding K<sub>m</sub> = 134 ± 5 µM, k<sub>cat</sub> = 31 ± 4 s<sup>−1</sup>, and k<sub>cat</sub>/K<sub>m</sub> = 1.4 ± 0.1 × 10<sup>7</sup> M<sup>−1</sup> min<sup>−1</sup>.</p>
<fig id="fig3-1087057112441012" position="float">
<label>Figure 3.</label>
<caption>
<p>Kinetic constants for 4-methylcoumarin butyrate (4MC-B) hydrolysis by monoglyceride lipase (MGLL). (<bold>A</bold>) Initial rate determination using 12 to 420 µM 4MC-B. (<bold>B</bold>) Plot of the initial velocities from <bold>A</bold> as a function of initial substrate concentrations fit to <xref ref-type="disp-formula" rid="disp-formula2-1087057112441012">equation (2)</xref> to give kinetic parameters reported in the text.</p>
</caption>
<graphic xlink:href="10.1177_1087057112441012-fig3.tif"/>
</fig>
</sec>
<sec id="section11-1087057112441012">
<title>IC <sub>50</sub> assay for inhibition screening</title>
<p>The MGLL activity assay was further evaluated using an active site inhibitor (<xref ref-type="fig" rid="fig4-1087057112441012"><bold>Fig. 4A</bold></xref>) that was identified as a possible tool compound during the HTS campaign described below.<sup><xref ref-type="bibr" rid="bibr15-1087057112441012">15</xref></sup> Progress curves for the hydrolysis of 4MC-B in the presence of the tool compound (<xref ref-type="fig" rid="fig4-1087057112441012"><bold>Fig. 4B</bold></xref>) are consistent with rapid, reversible inhibition. A plot of the initial reaction rates as a function of inhibitor concentration (<xref ref-type="fig" rid="fig4-1087057112441012"><bold>Fig. 4B</bold></xref>, inset) was fit to <xref ref-type="disp-formula" rid="disp-formula2-1087057112441012">equation (2)</xref>, giving IC<sub>50</sub> = 0.1 ± 0.02 µM, with a Hill slope of h = 1. The K<sub>i</sub> value for this compound, determined by varying both substrate and inhibitor concentrations (<xref ref-type="fig" rid="fig4-1087057112441012"><bold>Fig. 4C</bold></xref>), was described well by a global fit to a competitive binding model using <xref ref-type="disp-formula" rid="disp-formula1-1087057112441012">equation (1)</xref>, yielding K<sub>i</sub> = 0.2 ± 0.03 µM.</p>
<fig id="fig4-1087057112441012" position="float">
<label>Figure 4.</label>
<caption>
<p>Inhibition of monoglyceride lipase (MGLL) by a tool compound. (<bold>A</bold>) Structure of tool compound as described in Schalk-Hihi et al.<sup><xref ref-type="bibr" rid="bibr15-1087057112441012">15</xref></sup> (<bold>B</bold>) Progress curves for the hydrolysis of 4-methylcoumarin butyrate (4MC-B) at 0.01 to 15 µM of tool compound. Less than 10% of the substrate was hydrolyzed through 5 min. Inset shows initial velocity data for product formation as a function of inhibitor concentration, fit to <xref ref-type="disp-formula" rid="disp-formula3-1087057112441012">equation (3)</xref> to obtain an IC<sub>50</sub> estimate. (<bold>C</bold>) A K<sub>i</sub> was determined by varying both substrate and inhibitor concentrations, fit to <xref ref-type="disp-formula" rid="disp-formula1-1087057112441012">equation (1)</xref>, demonstrating competitive inhibition. Data represent no substrate control (closed circles), 0.24 µM inhibitor (open circles), and 1.9 µM inhibitor (closed, inverted triangles).</p>
</caption>
<graphic xlink:href="10.1177_1087057112441012-fig4.tif"/>
</fig>
</sec>
<sec id="section12-1087057112441012">
<title>High-throughput screen</title>
<p>An HTS campaign using ThermoFluor was performed testing compound libraries at (nominally) 22 µM.<sup><xref ref-type="bibr" rid="bibr17-1087057112441012">17</xref></sup>
<xref ref-type="fig" rid="fig5-1087057112441012"><bold>Figure 5A</bold></xref> illustrates the typical thermal stability transitions for the unfolding of MGLL in the absence and presence of several ligands. Each unfolding transition is characterized by a distinct <italic>T<sub>m</sub></italic>, the midpoint temperature of unfolding defined by <xref ref-type="disp-formula" rid="disp-formula4-1087057112441012">equation (4)</xref>. Ligand-binding affinities are determined from a series of thermal unfolding curves,<sup><xref ref-type="bibr" rid="bibr17-1087057112441012">17</xref></sup> as shown for several ligands (<xref ref-type="fig" rid="fig5-1087057112441012"><bold>Fig. 5B</bold></xref>). The <italic>T<sub>m</sub></italic> of MGLL changes in proportion to both the concentration and affinity of the ligand, defined by <xref ref-type="disp-formula" rid="disp-formula9-1087057112441012">equation (6b)</xref>. For all examples, a shift in Δ<italic>T<sub>m</sub></italic> continues to occur well above the concentration of MGLL (0.7 µM) used in the assays. The magnitude of Δ<italic>T<sub>m</sub></italic> (the increase in MGLL thermal stability) resulting from ligand binding is a function of both compound concentration and the dissociation constant for compound binding, K<sub>D</sub>.<sup>16–18,23</sup> For HTS assays, where all compounds are assayed at a single concentration, Δ<italic>T<sub>m</sub></italic> is directly proportional to binding affinity.</p>
<fig id="fig5-1087057112441012" position="float">
<label>Figure 5.</label>
<caption>
<p>Compound affinity by ThermoFluor. (<bold>A</bold>) Monoglyceride lipase (MGLL) thermal stability is increased in the presence of 0 µM (black circles) or 15 µM of several compound (compound structures not disclosed) the T<sub>m</sub> of unfolding is the midpoint temperature between folded and unfolded for each protein:ligand mixture. (<bold>B</bold>) Concentration-response curves for selected MGLL screening positives ranging from K<sub>D</sub> = 0.2 to 200 µM. Analysis of T<sub>m</sub> versus ligand concentration yielded K<sub>D</sub> values as described in the text. (<bold>C</bold>) Correlation of single-point stability perturbations ΔT<sub>m</sub> (~22 µM ligand) versus K<sub>D</sub> obtained from dose-response studies demonstrates the high information content of single-point ΔT<sub>m</sub> values.</p>
</caption>
<graphic xlink:href="10.1177_1087057112441012-fig5.tif"/>
</fig>
<p>Among the example compounds, one weak binding inhibitor (<xref ref-type="fig" rid="fig5-1087057112441012"><bold>Fig. 5B</bold></xref>, squares) is representative of ligands with a binding affinity near the upper concentration tested (~120 µM) and is more accurately assayed by increasing the ligand concentration.<sup><xref ref-type="bibr" rid="bibr16-1087057112441012">16</xref></sup> In contrast, the highest affinity compound shown for comparison has a K<sub>D</sub> = 0.5 µM (<xref ref-type="fig" rid="fig5-1087057112441012"><bold>Fig. 5B</bold></xref>, open circles), an affinity below the concentration of MGLL. For compounds with even tighter binding affinity, the shape of the curve takes on a sigmoidal appearance until the protein is saturated; these tight-binding profiles still allow for precise quantitation of the binding constant.<sup><xref ref-type="bibr" rid="bibr17-1087057112441012">17</xref>,<xref ref-type="bibr" rid="bibr23-1087057112441012">23</xref></sup> That same representative compound shows another common attribute of thermal shift assays, the effect of compound solubility limit on the concentration-response curve; the highest two to three concentrations of this compound are above its solubility limit (~5 µM by light scattering). The protein stability responds only to the amount of soluble ligand present in solution.</p>
<p>The compound ranking obtained from single-point stability-perturbation measurements correlates to that obtained from concentration-response curves. The Δ<italic>T<sub>m</sub></italic> determined from a single ligand concentration has a linear dependence with respect to the log of the binding constant (<xref ref-type="fig" rid="fig5-1087057112441012"><bold>Fig. 5C</bold></xref>). As shown for a number of HTS hits, there is a strong correlation between Δ<italic>T<sub>m</sub></italic> and log(K<sub>D</sub>), particularly when Δ<italic>T<sub>m</sub></italic> &gt; 1 °C, or roughly five to six times the standard deviation of the ligand-free <italic>T<sub>m</sub></italic> value for MGLL. For those compounds that generate a small Δ<italic>T<sub>m</sub></italic> &lt; 1 °C at the nominal concentration used in screening, there is a poor correlation between Δ<italic>T<sub>m</sub></italic> and log(K<sub>D</sub>).<sup><xref ref-type="bibr" rid="bibr16-1087057112441012">16</xref></sup></p>
</sec>
<sec id="section13-1087057112441012">
<title>Correlation between functional and binding activities</title>
<p>ThermoFluor screening positives were tested for their effect on enzyme activity using the 4-MC-B enzyme activity assay at a single concentration of compound to yield a percent inhibition. A correlation of confirmed positives relates % activity of MGLL versus Δ<italic>T<sub>m</sub></italic> (<xref ref-type="fig" rid="fig6-1087057112441012"><bold>Fig. 6A</bold></xref>). Most of the compounds that were discovered due to an effect on protein stability also affected the enzymatic activity, although this is not necessarily guaranteed (e.g., if a compound binds outside the protein active site). Compounds giving Δ<italic>T<sub>m</sub></italic> &lt; 1 °C generally exhibited less than 50% inhibition, whereas compounds giving a Δ<italic>T<sub>m</sub></italic> &gt; 1 °C generally exhibited greater than 50% inhibition.</p>
<fig id="fig6-1087057112441012" position="float">
<label>Figure 6.</label>
<caption>
<p>Correlation of compound functional inhibition (enzymatic activity) versus compound binding (by ThermoFluor). (<bold>A</bold>) Correlation using single-concentration tests, % inhibition, and ΔT<sub>m</sub> using 4 µM and 22 µM compound, respectively. Note the wide discrimination of highly active compounds (&gt;80% inhibition) when considering their differential effect on protein stability. (<bold>B</bold>) Correlation of IC<sub>50</sub> versus K<sub>D</sub> allows discrimination of compounds into several discrete groups: group 1, compounds with “good” correlation; group 2, compounds with activity underrepresented using the enzyme assay due to mass action effects; group 3, compounds that may bind outside the active site but lack activity; and group 4, compounds with apparent activity that do not bind to monoglyceride lipase (MGLL).</p>
</caption>
<graphic xlink:href="10.1177_1087057112441012-fig6.tif"/>
</fig>
</sec>
<sec id="section14-1087057112441012">
<title>Mechanism-of-action indications from orthogonal assay correlations</title>
<p>Compounds that were identified from the ThermoFluor-based HTS were further evaluated as MGLL inhibitors by measuring binding affinity, effect on enzyme activity, quality control (QC)/concentration analyses, and solubility (as in <xref ref-type="fig" rid="fig2-1087057112441012"><bold>Fig. 2</bold></xref>). The same source of compounds was used in all measurements to minimize differences in sample concentration or preparation when comparing activity in binding and enzyme assays. A plot of IC<sub>50</sub> versus K<sub>D</sub> clearly shows a clustering of compounds into four separate groups (<xref ref-type="fig" rid="fig6-1087057112441012"><bold>Fig. 6B</bold></xref>). Most compounds showed good correlation between ThermoFluor K<sub>D</sub> and IC<sub>50</sub> values (group 1). The variation between observed IC<sub>50</sub> and K<sub>D</sub> values is larger than is typically observed for sample replicates using the same technologies. Although measurements were made on the same compound source plate, they were not assayed within the same time frame, which may contribute to the observed variability.</p>
<p>In group 2 (<xref ref-type="fig" rid="fig6-1087057112441012"><bold>Fig. 6B</bold></xref>), the IC<sub>50</sub>s of compounds appear not to correlate with the K<sub>D</sub> values and give an apparent underestimation of compound potency in the activity assay relative to the binding assay. This was due to the sensitivity limit inherent to the enzymatic assay protocol, which was limited by the enzyme concentration (40 nM). Thus, all compounds with K<sub>D</sub> &lt; 40 nM only require 20 nM compound to achieve 50% inhibition of 40 nM MGLL, whereas K<sub>D</sub> values are well determined for very tight-binding inhibitors, although the protein concentration (1 µM) is ~100-fold greater than the affinity. The IC<sub>50</sub> curves for these compounds yielded Hill coefficients greater than 1, consistent with activity being limited by mass action.</p>
<p>An example of both a group 1 compound (fit with an IC<sub>50</sub> = 5.2 · 10<sup>−7</sup> M and <italic>h</italic> = 1) and a group 2 compound (either fit with a Hill coefficient fixed at <italic>h</italic> = 1 [IC<sub>50</sub> = 1.6 · 10<sup>−8</sup> M] or varied, giving IC<sub>50</sub> = 1.7 · 10<sup>−8</sup> M and <italic>h</italic> = 1.7) is compared in <xref ref-type="fig" rid="fig7-1087057112441012"><bold>Figure 7A</bold></xref>. The residuals for the group 2 compound clearly show that <italic>h</italic> = 1 inadequately describes the data. The concentration of MGLL had been reduced to 25 nM for these assays; compounds with an effective inhibition lower than approximately half the enzyme concentration are best described by the quadratic Morrison equation for tight-binding inhibitors.<sup><xref ref-type="bibr" rid="bibr24-1087057112441012">24</xref></sup> Using the quadratic Morrison equation, the fit and residuals of the group 2 compound were indistinguishable from the fit where IC<sub>50</sub> and <italic>h</italic> were varied (not shown). In general, additional replicates at varying [MGLL] at lower concentrations could help quantitate IC<sub>50</sub> values in this tight-binding regime. However, their affinities are readily distinguished from ThermoFluor-based K<sub>D</sub> measurements.</p>
<fig id="fig7-1087057112441012" position="float">
<label>Figure 7.</label>
<caption>
<p>IC<sub>50</sub> estimates and comparison of IC<sub>50</sub>s measured for short or long substrate: (<bold>A</bold>) Concentration response curves (CRCs) for selected inhibitors affecting 4-methylcoumarin butyrate (4MC-B) hydrolysis (10 µM), demonstrating weak affinity (squares) or high affinity (triangles). Data were analyzed according to <xref ref-type="disp-formula" rid="disp-formula3-1087057112441012">equation (3)</xref>, with h = 1 (solid lines) or with the Hill slope allowed to vary (dashed lines). Residuals of fits to tight-binding compound (triangles in <bold>A</bold>) with <italic>h</italic> = 1 (solid line) or with the Hill slope allowed to vary (dotted line). (<bold>B</bold>) Correlation of IC<sub>50</sub>s determined using substrates 4MC-B at 10 µM (K<sub>m</sub> 130 µM) and 4-methylcoumarin oleate (4MC-O) at 5 µM (K<sub>m</sub> &gt; 50 µM). Standard deviations represent <italic>n</italic> ≥ 2 for either assay.</p>
</caption>
<graphic xlink:href="10.1177_1087057112441012-fig7.tif"/>
</fig>
<p>Compounds in group 3 (<xref ref-type="fig" rid="fig6-1087057112441012"><bold>Fig. 6B</bold></xref>) reproducibly showed binding affinity by ThermoFluor (with K<sub>D</sub> values &lt;1 µM) yet had no effect on enzyme activity at concentrations up to 15 µM. To test for direct binding interactions, these same compounds were assayed using isothermal titration calorimetry (data not shown) and confirmed a lack of binding of group 3 compounds at 25 °C or 37 °C (two temperatures were chosen in case ΔH<sub>b</sub> ~0 kcal/mole at one of these temperatures). In this case, the binding observed using ThermoFluor is either due to compound binding preferentially at elevated temperatures or because compound binding is only observed in the presence of the ANS dye present in ThermoFluor experiments. In support of the former hypothesis, these same compounds also increased the protein thermal stability when monitoring protein stability via changes in tryptophan fluorescence (data not shown). For other compounds associated with other HTS programs, the latter hypothesis has also been confirmed through the use of ThermoFluor using a different reporter dye. Regardless, these compounds were not pursued further.</p>
<p>Group 4 compounds (<xref ref-type="fig" rid="fig6-1087057112441012"><bold>Fig. 6B</bold></xref>) displayed IC<sub>50</sub> values in the 5- to 10-µM range but showed no or little apparent binding by ThermoFluor at concentrations &gt;70 µM in concentration-response studies. Such behavior might be expected for compounds that could quench product fluorescence in the enzyme assay or that are thermally unstable. Either of these artifacts can make it difficult to determine a binding constant in ThermoFluor precisely, especially for weak binding compounds (K<sub>D</sub> &gt; 5 µM). Regardless, the highest priority would be given to compounds in groups 1 and 2 as potential lead molecules in a subsequent drug discovery lead optimization program for MGLL inhibition.</p>
</sec>
</sec>
<sec id="section15-1087057112441012" sec-type="discussion">
<title>Discussion</title>
<p>Our strategy for discovery of potent monoacylglycerol lipase inhibitors was to first conduct a high-throughput screen employing a ThermoFluor-based binding assay applied to MGLL and a proprietary compound library. Second, it was necessary to develop a rate-based fluorescent assay for monoacylglycerol lipase to confirm functional activity of compounds discovered via the binding HTS assay. Validation included both single-point and concentration-response curves for both ThermoFluor and enzyme activity. Furthermore, compounds that showed a similar rank order across both assays were selected for compound development activities. The detailed comparison of affinities from the binding assay, K<sub>D</sub>s, and from the enzymatic assay, IC<sub>50</sub>s, was used to develop additional insights into the mechanism of ligand action and to eliminate false-positive compounds from either method.</p>
<p>During assay development, proper determination of substrate kinetic constants is critical in that they form the basis for selecting concentrations of enzyme and substrate in screening assays and for addressing inhibitor mechanism-of-action for compounds identified from HTS. Although the products of monoacylglycerol hydrolysis, arachidonic acid and glycerol, can be monitored through liquid chromatography/mass spectrometry (LC/MS) and radioactive methods, such methods are cumbersome for large-scale screening of compound libraries. The incorporation of an optical probe attached to the substrate allows for spectroscopic differentiation of substrates and products and importantly lends itself to assay miniaturization. A rate-based kinetic assay, in lieu of an end-point assay, minimizes contributions from spectroscopic artifacts (e.g., compound absorbance or fluorescence) that can give rise to false-positive or false-negative results.</p>
<p>Another challenge commonly encountered for enzymes involved in fatty acid metabolism is intrinsic to the reactants and products of enzymatic reactions. For MGLL, the low solubility of substrates with aliphatic chains longer than butyrate made it difficult to determine their kinetic constants. Generally, it is important to ensure that surrogates of the natural enzyme substrate are functionally relevant in comparison to the native reactions, as exemplified here by the challenge of substantially truncated acyl chain lengths employed out of the necessity to improve substrate solubility. Although solubility limits of substrates prohibited quantitation of kinetic constants for all but 4MC-B, a comparison of initial rate data for all substrates as dilute solutions confirmed comparable initial velocities (data not shown). Initial rates versus total substrate concentration for these substrates yielded apparent hyperbolic curves, where substrate concentrations had reached their respective solubility limits (data not shown). Minimally, initial velocity data provided supporting evidence that substrate utilization is comparable for the 4MC-B substrate in comparison to substrates with longer acyl chains.</p>
<p>Another concern is associated with the use of the short aliphatic chain substrate as a surrogate for the natural, longer aliphatic chain for MGLL activity. Truncated substrates could potentially yield different structure-activity relationships (SARs) than one with a longer aliphatic chain. Therefore, a small number of compounds were assayed for MGLL inhibition using the larger 4MC-O substrate, 10-fold below the solubility limit of this substrate and well below the K<sub>m</sub> of 4MC-B. A correlation plot of IC<sub>50</sub> values determined using 4MC-O and 4MC-B displayed excellent correlation between inhibitors of the oleate- versus butyrate-based fluorescent substrate (<xref ref-type="fig" rid="fig7-1087057112441012"><bold>Fig. 7B</bold></xref>). These data validate routine use of the shorter substrate to monitor the SAR of MGLL inhibitors.</p>
<p>Recently, several studies of MGLL have been published that use a similar approach of labeling alkyl chains with absorbance- or fluorescent-based spectrophotometric dyes. Muccioli et al.<sup><xref ref-type="bibr" rid="bibr25-1087057112441012">25</xref></sup> employed the chromogenic moiety, 4-nitrophenol, in several alkyl esters that were successfully hydrolyzed by MGLL in absorbance-based assays. Similarly, Wang and coworkers<sup><xref ref-type="bibr" rid="bibr26-1087057112441012">26</xref></sup> used 7-hydroxycoumarinyl-arachidonate in an HTS campaign for the discovery of competitive MGLL inhibitors. These studies benefit from the same approach that was undertaken in our current research, incorporating spectroscopic probes into various alkyl chains of different length and degree of saturation. However, our approach has been to rank MGLL ligands via the orthogonal techniques of binding and activity assays followed in parallel. Using a common source plate for assays, normalizing for compound concentration, and including solubility and QC measurements all serve to maximize our capacity to discern how small but significant chemical changes can affect compound mechanism of action.</p>
<p>It is common in ThermoFluor-based HTS to discover ligands that bind to a target protein outside of the active site; these may have no effect on enzyme activity or, conversely, may be allosteric modulators of activity. Likewise, it is common in activity-based assays to identify ligands that appear to affect enzymatic activity but do so in a manner that is not consistent with competitive substrate binding, as is the case for chelating or denaturing agents. A distinct benefit of using a ThermoFluor stability assay for the initial HTS is that compound affinities from the single-concentration measurements are well resolved based on Δ<italic>T<sub>m</sub></italic> (for compounds where Δ<italic>T<sub>m</sub></italic> &gt; 1 °C), whereas a similar single-point enzyme screen ranks numerous compounds equivalently as giving ~100% inhibition. Relative compound activity cannot be discriminated using enzyme inhibition assays without dose-response studies.</p>
<p>A comparison of ThermoFluor-derived binding constants, K<sub>D</sub>s, and kinetic inhibition of 4MC-B hydrolysis, IC<sub>50</sub>s, allowed for classification of compounds into four groups (<xref ref-type="fig" rid="fig6-1087057112441012"><bold>Fig. 6B</bold></xref>). Most compounds were in group 1 and were essentially equivalent in both binding and activity assays. The subset of compounds in group 2 were more potent in the binding assay as compared with the enzyme assay because affinities fell below the enzyme concentration employed in the activity assay. These highly active compounds are often difficult to discriminate when probed exclusively by an enzymatic assay, when further dilutions of the enzyme may not be practical in efforts to extend the lower limit of quantitation. A unique feature of the thermal shift assay is its utility with respect to quantifying binding affinities of extremely high-affinity ligands, in the range of sub-nanomolar K<sub>D</sub> values. The compounds in both groups 3 and 4 were only active in either the binding assay or the enzymatic assay, respectively. Regardless of the nature of these results, whether artifacts or legitimately active, pragmatically only compounds that are confirmed to bind and affect MGLL function were selected for further studies in the drug discovery program.</p>
<p>The combination of a binding assay, both initially for HTS and subsequently for affinity estimates, and a spectroscopic enzymatic assay, employing a soluble surrogate of the native reaction, were key tools in the discovery of MGLL inhibitors. The strength of combining parallel, orthogonal techniques at the stage of in vitro discovery bolsters our ability to prioritize compounds that have the best chance of showing activity in the next stages of discovery. This combination of approaches highlights the strengths and limitations of either approach when undertaken alone but importantly provides an efficient means of eliminating compounds with inconsistent activity without the need for further evaluation. Finally, this work is a step forward in expediting the identification of inhibitors against MGLL, a key factor in the future development of antinociception therapeutics targeting the cannabinoid system.</p>
</sec>
</body>
<back>
<ack><p>The authors thank Mark E. McDonnell and Mark J. Macielag at Janssen Research &amp; Development, LLC, Spring House, Pennsylvania, for synthesis of the MGLL tool compound.</p></ack>
<fn-group>
<fn fn-type="conflict">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The research represents work done in the course of employment; there was no financial support above and beyond normal compensation for employees.</p>
</fn>
<fn fn-type="other" id="fn1-1087057112441012">
<label>*</label>
<p>The ThermoFluor assay was developed by 3-Dimensional Pharmaceuticals, Inc., which has been merged into Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C. ThermoFluor is a trademark registered in the United States and certain other countries and is protected under U.S. patents US6020141, US6036920, US6214293, US6232085, US6268158, US6268218, US6291191, US6291192, and US6303322.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1087057112441012">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hohmann</surname><given-names>A. G.</given-names></name>
</person-group> <article-title>Spinal and Peripheral Mechanisms of Cannabinoid Antinociception: Behavioral, Neurophysiological and Neuroanatomical Perspectives</article-title>. <source>Chem. Phys. Lipids</source> <year>2002</year>, <volume>121</volume>(<issue>1–2</issue>), <fpage>173</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr2-1087057112441012">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malan</surname><given-names>T. P.</given-names><suffix>Jr.</suffix></name>
<name><surname>Ibrahim</surname><given-names>M. M.</given-names></name>
<name><surname>Vanderah</surname><given-names>T. W.</given-names></name>
<name><surname>Makriyannis</surname><given-names>A.</given-names></name>
<name><surname>Porreca</surname><given-names>F.</given-names></name>
</person-group> <article-title>Inhibition of Pain Responses by Activation of CB(2) Cannabinoid Receptors</article-title>. <source>Chem. Phys. Lipids</source> <year>2002</year>, <volume>121</volume>(<issue>1–2</issue>), <fpage>191</fpage>–<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr3-1087057112441012">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bloom</surname><given-names>A. S.</given-names></name>
<name><surname>Dewey</surname><given-names>W. L.</given-names></name>
<name><surname>Harris</surname><given-names>L. S.</given-names></name>
<name><surname>Brosius</surname><given-names>K. K.</given-names></name>
</person-group> <article-title>9-Nor-9beta-hydroxyhexahydrocannabinol, a Cannabinoid with Potent Antinociceptive Activity: Comparisons with Morphine</article-title>. <source>J. Pharmacol. Exp. Ther</source>. <year>1977</year>, <volume>200</volume>(<issue>2</issue>), <fpage>263</fpage>–<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr4-1087057112441012">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guindon</surname><given-names>J.</given-names></name>
<name><surname>Desroches</surname><given-names>J.</given-names></name>
<name><surname>Beaulieu</surname><given-names>P.</given-names></name>
</person-group> <article-title>The Antinociceptive Effects of Intraplantar Injections of 2-Arachidonoyl Glycerol Are Mediated by Cannabinoid CB2 Receptors</article-title>. <source>Br. J. Pharmacol</source>. <year>2007</year>, <volume>150</volume>(<issue>6</issue>), <fpage>693</fpage>–<lpage>701</lpage>.</citation>
</ref>
<ref id="bibr5-1087057112441012">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kosersky</surname><given-names>D. S.</given-names></name>
<name><surname>Dewey</surname><given-names>W. L.</given-names></name>
<name><surname>Harris</surname><given-names>L. S.</given-names></name>
</person-group> <article-title>Antipyretic, Analgesic and Anti-Inflammatory Effects of Delta 9-Tetrahydrocannabinol in the Rat</article-title>. <source>Eur. J. Pharmacol</source>. <year>1973</year>, <volume>24</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr6-1087057112441012">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mechoulam</surname><given-names>R.</given-names></name>
<name><surname>Ben-Shabat</surname><given-names>S.</given-names></name>
<name><surname>Hanus</surname><given-names>L.</given-names></name>
<name><surname>Ligumsky</surname><given-names>M.</given-names></name>
<name><surname>Kaminski</surname><given-names>N. E.</given-names></name>
<name><surname>Schatz</surname><given-names>A. R.</given-names></name>
<name><surname>Gopher</surname><given-names>A.</given-names></name>
<name><surname>Almog</surname><given-names>S.</given-names></name>
<name><surname>Martin</surname><given-names>B. R.</given-names></name>
<name><surname>Compton</surname><given-names>D. R.</given-names></name>
<etal/>
</person-group>. <article-title>Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors</article-title>. <source>Biochem. Pharmacol</source>. <year>1995</year>, <volume>50</volume>(<issue>1</issue>), <fpage>83</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr7-1087057112441012">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sugiura</surname><given-names>T.</given-names></name>
<name><surname>Kondo</surname><given-names>S.</given-names></name>
<name><surname>Sukagawa</surname><given-names>A.</given-names></name>
<name><surname>Nakane</surname><given-names>S.</given-names></name>
<name><surname>Shinoda</surname><given-names>A.</given-names></name>
<name><surname>Itoh</surname><given-names>K.</given-names></name>
<name><surname>Yamashita</surname><given-names>A.</given-names></name>
<name><surname>Waku</surname><given-names>K.</given-names></name>
</person-group> <article-title>2-Arachidonoylglycerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain</article-title>. <source>Biochem. Biophys. Res. Commun</source>. <year>1995</year>, <volume>215</volume>(<issue>1</issue>), <fpage>89</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr8-1087057112441012">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Makara</surname><given-names>J. K.</given-names></name>
<name><surname>Mor</surname><given-names>M.</given-names></name>
<name><surname>Fegley</surname><given-names>D.</given-names></name>
<name><surname>Szabo</surname><given-names>S. I.</given-names></name>
<name><surname>Kathuria</surname><given-names>S.</given-names></name>
<name><surname>Astarita</surname><given-names>G.</given-names></name>
<name><surname>Duranti</surname><given-names>A.</given-names></name>
<name><surname>Tontini</surname><given-names>A.</given-names></name>
<name><surname>Tarzia</surname><given-names>G.</given-names></name>
<name><surname>Rivara</surname><given-names>S.</given-names></name>
<etal/>
</person-group>. <article-title>Selective Inhibition of 2-AG Hydrolysis Enhances Endocannabinoid Signaling in Hippocampus</article-title>. <source>Nat. Neurosci</source>. <year>2005</year>, <volume>8</volume>(<issue>9</issue>), <fpage>1139</fpage>–<lpage>1141</lpage>.</citation>
</ref>
<ref id="bibr9-1087057112441012">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bertrand</surname><given-names>T.</given-names></name>
<name><surname>Auge</surname><given-names>F.</given-names></name>
<name><surname>HouTmann</surname><given-names>J.</given-names></name>
<name><surname>Rak</surname><given-names>A.</given-names></name>
<name><surname>Vallee</surname><given-names>F.</given-names></name>
<name><surname>Mikol</surname><given-names>V.</given-names></name>
<name><surname>Berne</surname><given-names>P. F.</given-names></name>
<name><surname>Michot</surname><given-names>N.</given-names></name>
<name><surname>Cheuret</surname><given-names>D.</given-names></name>
<name><surname>Hoornaert</surname><given-names>C.</given-names></name>
<etal/>
</person-group>. <article-title>Structural Basis for Human Monoglyceride Lipase Inhibition</article-title>. <source>J. Mol. Biol</source>. <year>2010</year>, <volume>396</volume>(<issue>3</issue>), <fpage>663</fpage>–<lpage>673</lpage>.</citation>
</ref>
<ref id="bibr10-1087057112441012">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Labar</surname><given-names>G.</given-names></name>
<name><surname>Bauvois</surname><given-names>C.</given-names></name>
<name><surname>Muccioli</surname><given-names>G. G.</given-names></name>
<name><surname>Wouters</surname><given-names>J.</given-names></name>
<name><surname>Lambert</surname><given-names>D. M.</given-names></name>
</person-group> <article-title>Disulfiram Is an Inhibitor of Human Purified Monoacylglycerol Lipase, the Enzyme Regulating 2-Arachidonoylglycerol Signaling</article-title>. <source>Chembiochem</source> <year>2007</year>, <volume>8</volume>(<issue>11</issue>), <fpage>1293</fpage>–<lpage>1297</lpage>.</citation>
</ref>
<ref id="bibr11-1087057112441012">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bode</surname><given-names>W.</given-names></name>
<name><surname>Mayr</surname><given-names>I.</given-names></name>
<name><surname>Baumann</surname><given-names>U.</given-names></name>
<name><surname>Huber</surname><given-names>R.</given-names></name>
<name><surname>Stone</surname><given-names>S. R.</given-names></name>
<name><surname>Hofsteenge</surname><given-names>J.</given-names></name>
</person-group> <article-title>The Refined 1.9 A Crystal Structure of Human Alpha-Thrombin: Interaction with D-Phe-Pro-Arg Chloromethylketone and Significance of the Tyr-Pro-Pro-Trp Insertion Segment</article-title>. <source>EMBO J</source>. <year>1989</year>, <volume>8</volume>(<issue>11</issue>), <fpage>3467</fpage>–<lpage>3475</lpage>.</citation>
</ref>
<ref id="bibr12-1087057112441012">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Desarnaud</surname><given-names>F.</given-names></name>
<name><surname>Cadas</surname><given-names>H.</given-names></name>
<name><surname>Piomelli</surname><given-names>D.</given-names></name>
</person-group> <article-title>Anandamide Amidohydrolase Activity in Rat Brain Microsomes: Identification and Partial Characterization</article-title>. <source>J. Biol. Chem</source>. <year>1995</year>, <volume>270</volume>(<issue>11</issue>), <fpage>6030</fpage>–<lpage>6035</lpage>.</citation>
</ref>
<ref id="bibr13-1087057112441012">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vila</surname><given-names>A.</given-names></name>
<name><surname>Rosengarth</surname><given-names>A.</given-names></name>
<name><surname>Piomelli</surname><given-names>D.</given-names></name>
<name><surname>Cravatt</surname><given-names>B.</given-names></name>
<name><surname>Marnett</surname><given-names>L. J.</given-names></name>
</person-group> <article-title>Hydrolysis of Prostaglandin Glycerol Esters by the Endocannabinoid-Hydrolyzing Enzymes, Monoacylglycerol Lipase and Fatty Acid Amide Hydrolase</article-title>. <source>Biochemistry</source> <year>2007</year>, <volume>46</volume>(<issue>33</issue>), <fpage>9578</fpage>–<lpage>9585</lpage>.</citation>
</ref>
<ref id="bibr14-1087057112441012">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savinainen</surname><given-names>J. R.</given-names></name>
<name><surname>Yoshino</surname><given-names>M.</given-names></name>
<name><surname>Minkkila</surname><given-names>A.</given-names></name>
<name><surname>Nevalainen</surname><given-names>T.</given-names></name>
<name><surname>Laitinen</surname><given-names>J. T.</given-names></name>
</person-group> <article-title>Characterization of Binding Properties of Monoglyceride Lipase Inhibitors by a Versatile Fluorescence-Based Technique</article-title>. <source>Anal. Biochem</source>. <year>2010</year>, <volume>399</volume>(<issue>1</issue>), <fpage>132</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr15-1087057112441012">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schalk-Hihi</surname><given-names>C.</given-names></name>
<name><surname>Schubert</surname><given-names>C.</given-names></name>
<name><surname>Alexander</surname><given-names>R.</given-names></name>
<name><surname>Bayoumy</surname><given-names>S.</given-names></name>
<name><surname>Clemente</surname><given-names>J. C.</given-names></name>
<name><surname>Deckman</surname><given-names>I.</given-names></name>
<name><surname>DesJarlais</surname><given-names>R. L.</given-names></name>
<name><surname>Dzordzorme</surname><given-names>K. C.</given-names></name>
<name><surname>Flores</surname><given-names>C. M.</given-names></name>
<name><surname>Grasberger</surname><given-names>B.</given-names></name>
<etal/>
</person-group>. <article-title>Crystal Structure of a Soluble Form of Human Monoglyceride Lipase in Complex with an Inhibitor at 1.35 A Resolution</article-title>. <source>Protein Sci</source>. <year>2011</year>, <volume>20</volume>(<issue>4</issue>), <fpage>670</fpage>–<lpage>683</lpage>.</citation>
</ref>
<ref id="bibr16-1087057112441012">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kranz</surname><given-names>J. K.</given-names></name>
<name><surname>Schalk-Hihi</surname><given-names>C.</given-names></name>
</person-group> <article-title>Protein Thermal Shifts to Identify Low Molecular Weight Fragments</article-title>. <source>Methods Enzymol</source>. <year>2011</year>, <volume>493</volume>, <fpage>277</fpage>–<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr17-1087057112441012">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matulis</surname><given-names>D.</given-names></name>
<name><surname>Kranz</surname><given-names>J. K.</given-names></name>
<name><surname>Salemme</surname><given-names>F. R.</given-names></name>
<name><surname>Todd</surname><given-names>M. J.</given-names></name>
</person-group> <article-title>Thermodynamic Stability of Carbonic Anhydrase: Measurements of Binding Affinity and Stoichiometry Using ThermoFluor</article-title>. <source>Biochemistry</source> <year>2005</year>, <volume>44</volume>(<issue>13</issue>), <fpage>5258</fpage>–<lpage>5266</lpage>.</citation>
</ref>
<ref id="bibr18-1087057112441012">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pantoliano</surname><given-names>M. W.</given-names></name>
<name><surname>Petrella</surname><given-names>E. C.</given-names></name>
<name><surname>Kwasnoski</surname><given-names>J. D.</given-names></name>
<name><surname>Lobanov</surname><given-names>V. S.</given-names></name>
<name><surname>Myslik</surname><given-names>J.</given-names></name>
<name><surname>Graf</surname><given-names>E.</given-names></name>
<name><surname>Carver</surname><given-names>T.</given-names></name>
<name><surname>Asel</surname><given-names>E.</given-names></name>
<name><surname>Springer</surname><given-names>B. A.</given-names></name>
<name><surname>Lane</surname><given-names>P.</given-names></name>
<etal/>
</person-group>. <article-title>High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery</article-title>. <source>J. Biomol. Screen</source>. <year>2001</year>, <volume>6</volume>(<issue>6</issue>), <fpage>429</fpage>–<lpage>440</lpage>.</citation>
</ref>
<ref id="bibr19-1087057112441012">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cummings</surname><given-names>M. D.</given-names></name>
<name><surname>Farnum</surname><given-names>M. A.</given-names></name>
<name><surname>Nelen</surname><given-names>M. I.</given-names></name>
</person-group> <article-title>Universal Screening Methods and Applications of ThermoFluor</article-title>. <source>J. Biomol. Screen</source>. <year>2006</year>, <volume>11</volume>(<issue>7</issue>), <fpage>854</fpage>–<lpage>863</lpage>.</citation>
</ref>
<ref id="bibr20-1087057112441012">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Nishi</surname><given-names>K.</given-names></name>
<name><surname>Tsai</surname><given-names>H. J.</given-names></name>
<name><surname>Hammock</surname><given-names>B. D.</given-names></name>
</person-group> <article-title>Development of Highly Sensitive Fluorescent Assays for Fatty Acid Amide Hydrolase</article-title>. <source>Anal. Biochem</source>. <year>2007</year>, <volume>363</volume>(<issue>1</issue>), <fpage>12</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr21-1087057112441012">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kage</surname><given-names>K. L.</given-names></name>
<name><surname>Richardson</surname><given-names>P. L.</given-names></name>
<name><surname>Traphagen</surname><given-names>L.</given-names></name>
<name><surname>Severin</surname><given-names>J.</given-names></name>
<name><surname>Pereda-Lopez</surname><given-names>A.</given-names></name>
<name><surname>Lubben</surname><given-names>T.</given-names></name>
<name><surname>Davis-Taber</surname><given-names>R.</given-names></name>
<name><surname>Vos</surname><given-names>M. H.</given-names></name>
<name><surname>Bartley</surname><given-names>D.</given-names></name>
<name><surname>Walter</surname><given-names>K.</given-names></name>
<etal/>
</person-group>. <article-title>A High Throughput Fluorescent Assay for Measuring the Activity of Fatty Acid Amide Hydrolase</article-title>. <source>J. Neurosci. Methods</source> <year>2007</year>, <volume>161</volume>(<issue>1</issue>), <fpage>47</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr22-1087057112441012">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramarao</surname><given-names>M. K.</given-names></name>
<name><surname>Murphy</surname><given-names>E. A.</given-names></name>
<name><surname>Shen</surname><given-names>M. W.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Bushell</surname><given-names>K. N.</given-names></name>
<name><surname>Huang</surname><given-names>N.</given-names></name>
<name><surname>Pan</surname><given-names>N.</given-names></name>
<name><surname>Williams</surname><given-names>C.</given-names></name>
<name><surname>Clark</surname><given-names>J. D.</given-names></name>
</person-group> <article-title>A Fluorescence-Based Assay for Fatty Acid Amide Hydrolase Compatible with High-Throughput Screening</article-title>. <source>Anal. Biochem</source>. <year>2005</year>, <volume>343</volume>(<issue>1</issue>), <fpage>143</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr23-1087057112441012">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brandts</surname><given-names>J. F.</given-names></name>
<name><surname>Lin</surname><given-names>L. N.</given-names></name>
</person-group> <article-title>Study of Strong to Ultratight Protein Interactions Using Differential Scanning Calorimetry</article-title>. <source>Biochemistry</source> <year>1990</year>, <volume>29</volume>(<issue>29</issue>), <fpage>6927</fpage>–<lpage>6940</lpage>.</citation>
</ref>
<ref id="bibr24-1087057112441012">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrison</surname><given-names>J. F.</given-names></name>
</person-group> <article-title>Kinetics of the Reversible Inhibition of Enzyme-Catalysed Reactions by Tight-Binding Inhibitors</article-title>. <source>Biochim. Biophys. Acta</source> <year>1969</year>, <volume>185</volume>(<issue>2</issue>), <fpage>269</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr25-1087057112441012">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muccioli</surname><given-names>G. G.</given-names></name>
<name><surname>Labar</surname><given-names>G.</given-names></name>
<name><surname>Lambert</surname><given-names>D. M.</given-names></name>
</person-group> <article-title>CAY10499, a Novel Monoglyceride Lipase Inhibitor Evidenced by an Expeditious MGL Assay</article-title>. <source>Chembiochem</source> <year>2008</year>, <volume>9</volume>(<issue>16</issue>), <fpage>2704</fpage>–<lpage>2710</lpage>.</citation>
</ref>
<ref id="bibr26-1087057112441012">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Chanda</surname><given-names>P.</given-names></name>
<name><surname>Jones</surname><given-names>P. G.</given-names></name>
<name><surname>Kennedy</surname><given-names>J. D.</given-names></name>
</person-group> <article-title>A Fluorescence-Based Assay for Monoacylglycerol Lipase Compatible with Inhibitor Screening</article-title>. <source>Assay Drug Dev. Technol</source>. <year>2008</year>, <volume>6</volume>(<issue>3</issue>), <fpage>387</fpage>–<lpage>393</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>